Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 11 · newest first

  1. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metforminBlood · 2018
  2. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVORBlood · 2018
  3. Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myelomaBritish Journal of Haematology · 2018
  4. Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece––the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)Expert Review of Pharmacoeconomics & Outcomes Research · 2018
  5. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingBlood Cancer Journal · 2018
  6. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple MyelomaNew England Journal of Medicine · 2018
  7. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT studyBlood Cancer Journal · 2018
  8. Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaAdvances in Therapy · 2018
  9. IMiDs for myeloma induced renal impairmentOncotarget · 2018
  10. Prognostic factors for multiple myeloma in the era of novel therapiesExpert Review of Hematology · 2018
  11. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupBlood Cancer Journal · 2018
  12. Management of multiple myeloma bone disease: impact of treatment on renal functionExpert Review of Hematology · 2018
  13. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosisAmyloid · 2018
  14. Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapyCancer Medicine · 2018
  15. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXHaematologica · 2018
  16. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trialCancer · 2018
  17. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and whenHaematologica · 2018
  18. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUSLeukemia & lymphoma/Leukemia and lymphoma · 2018
  19. Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practiceEuropean Journal Of Haematology · 2018
  20. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional StudyClinical Lymphoma Myeloma & Leukemia · 2018
  21. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s MacroglobulinemiaNew England Journal of Medicine · 2018
  22. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosisBlood Cancer Journal · 2018
  23. Optimizing therapy in bortezomib-exposed patients with multiple myelomaExpert Review of Hematology · 2018
  24. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroupsLeukemia · 2018
  25. Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR.Journal of Clinical Oncology · 2018
  26. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myelomaLeukemia & lymphoma/Leukemia and lymphoma · 2018
  27. Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myelomaBlood Cancer Journal · 2018
  28. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma NetworkLeukemia · 2018
  29. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trialLeukemia · 2018
  30. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX studyBlood Cancer Journal · 2018
  31. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology · 2018
  32. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE studyJournal of Hematology & Oncology · 2018
  33. Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependentOncotarget · 2018
  34. Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)Annals of Translational Medicine · 2018
  35. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?Annals of Translational Medicine · 2018
  36. Treating ALK-positive non-small cell lung cancerAnnals of Translational Medicine · 2018
  37. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study GroupBlood Cancer Journal · 2018
  38. Alcohol consumption and risk of hematological malignancies: A meta‐analysis of prospective studiesInternational Journal of Cancer · 2018
  39. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II TrialJournal of Clinical Oncology · 2018
  40. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosisBlood · 2018
  41. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaJournal of Clinical Oncology · 2018
  42. Pathogenesis of bone disease in multiple myeloma: from bench to bedsideBlood Cancer Journal · 2018
  43. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysisClinical Lymphoma Myeloma & Leukemia · 2018
  44. Cardio-oncology: A Focus on CardiotoxicityEuropean Cardiology Review · 2018
  45. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma networkLeukemia · 2017
  46. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse eventsScientific Reports · 2017
  47. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaNew England Journal of Medicine · 2017
  48. Diffuse Medullary Hyperdensities of the Femora and Humeri on Whole-Body Low-Dose Computed Tomography Identify Diffuse MRI Pattern of Involvement and Correlate with Advanced Disease Stage in Patients with Multiple MyelomaBlood · 2017
  49. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectivesHaematologica · 2017
  50. Efficacy of Lenalidomide As Salvage Therapy for Patients with AL AmyloidosisBlood · 2017